Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18659215 | PH20 Polypeptide Variants, Formulations and Uses Thereof | May 2024 | November 2024 | Allow | 6 | 2 | 0 | No | No |
| 18530981 | Treatment Of Uterine Fibroids Using Purified Collagenase | December 2023 | June 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18446826 | METHODS AND COMPOSITIONS FOR ISOLATION AND RAPID DETECTION OF MICRO-ORGANISMS FROM BLOOD AND BODILY FLUIDS | August 2023 | October 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18340482 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | June 2023 | March 2024 | Allow | 8 | 1 | 1 | No | No |
| 18330411 | PROTEIN FOR RAPID, EFFICIENT CAPTURE OF ANTIGENS | June 2023 | December 2024 | Allow | 18 | 1 | 0 | No | No |
| 18198519 | Treatment delivery system and method | May 2023 | January 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18315255 | MODIFIED BACTERIOPHAGE | May 2023 | January 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18309590 | High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal Antibody | April 2023 | September 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18186793 | NOVEL ANTI-PD-1 ANTIBODIES | March 2023 | May 2025 | Abandon | 26 | 2 | 0 | Yes | No |
| 18185979 | FUSION PROTEIN FOR DETECTING NEUROSYPHILIS AND KIT THEREOF | March 2023 | August 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18180976 | METHODS AND COMPOSITIONS FOR ISOLATION AND RAPID DETECTION OF MICRO-ORGANISMS FROM BLOOD AND BODILY FLUIDS | March 2023 | October 2024 | Abandon | 19 | 1 | 0 | No | No |
| 18153483 | LAWSONIA INTRACELLULARIS COMPOSITIONS AND METHODS OF USING THE SAME | January 2023 | August 2024 | Abandon | 19 | 0 | 1 | No | No |
| 18069265 | NOVEL MUTANT OF RECOMBINANT GANODERMA LUCIDUM IMMUNOMODULATORY PROTEIN AND USE THEREOF | December 2022 | October 2024 | Abandon | 22 | 2 | 1 | Yes | No |
| 17985317 | LACTOBACILLUS HELVETICUS ZJUIDS12 FOR TREATING ALCOHOLIC LIVER DISEASE AND APPLICATION THEREOF | November 2022 | February 2024 | Abandon | 15 | 2 | 0 | No | No |
| 17915527 | APPLICATION OF GERANIOL IN PREPARATION OF FORMULATION FOR PROMOTING SYNTHESIS OF PSEUDOMONAS AERUGINOSA 3OC12-HSL SIGNAL MOLECULES | September 2022 | March 2025 | Abandon | 29 | 3 | 0 | Yes | No |
| 17947083 | METHODS AND USES OF MICROBIOME COMPOSITIONS, COMPONENTS, OR METABOLITES FOR TREATING NEURODEGENERATIVE DISEASES | September 2022 | December 2023 | Allow | 15 | 2 | 1 | No | No |
| 17816045 | Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants | July 2022 | March 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17795329 | BACTERIAL ADMIXTURES | July 2022 | May 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17766738 | METHOD FOR PREPARING IMMOBILIZED ARGININE DEIMINASE (ADI) AND PRODUCING [14/15N]-L-CITRULLINE | April 2022 | May 2025 | Allow | 37 | 4 | 1 | Yes | No |
| 17669152 | Compositions, Devices, Kits and Methods for Detecting Hookworm | February 2022 | October 2023 | Abandon | 20 | 2 | 0 | No | No |
| 17650487 | Attenuated Bordetella Strains | February 2022 | December 2024 | Abandon | 35 | 3 | 0 | No | No |
| 17623072 | BOTULINUM TOXIN TYPE A COMPLEX, AND FORMULATION THEREOF AND USAGE METHOD THEREFOR | December 2021 | April 2025 | Allow | 40 | 2 | 1 | No | No |
| 17453305 | Use of an antibody and antisense in the treatment of Congenital Muscular Dystrophy | November 2021 | August 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17598652 | GARLIC EXTRACT AND METHOD THEREOF | September 2021 | October 2024 | Allow | 36 | 2 | 0 | No | No |
| 17483920 | PROTEINS WITH DIAGNOSTIC AND THERAPEUTIC USES | September 2021 | June 2025 | Abandon | 45 | 2 | 1 | No | No |
| 17468490 | TREATMENT OF VASOPRESSOR-INDUCED DIGITAL ISCHEMIA WITH BOTULINUM TOXIN A | September 2021 | September 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17434551 | LAWSONIA INTRACELLULARIS COMPOSITIONS AND METHODS OF USING THE SAME | August 2021 | January 2023 | Abandon | 17 | 0 | 1 | No | No |
| 17433067 | PRODUCTION OF HIGH PURITY ORGANIC LACTIC ACID AND ITS SALTS AND VARIOUS APPLICATIONS THEREOF | August 2021 | January 2025 | Allow | 41 | 3 | 0 | Yes | No |
| 17400790 | USE OF VARIOVORAX MICROBES AS AN ALTERNATIVE TREATMENT FOR COCCIDIOSIS | August 2021 | March 2025 | Abandon | 43 | 2 | 0 | Yes | Yes |
| 17426275 | VACCINE COMPOSITION FOR PREVENTING TUBERCULOSIS, COMPRISING GLYCOSYLATED AG85A PROTEIN AND METHOD FOR PREPARING SAME | July 2021 | September 2024 | Abandon | 38 | 3 | 1 | No | No |
| 17385958 | METHOD FOR IDENTIFYING AND TREATING STREPTOCOCCUS PYOGENES INFECTION | July 2021 | December 2024 | Abandon | 41 | 3 | 1 | No | No |
| 17422654 | ETHANOL | July 2021 | November 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17372291 | BACTERIAL-DERIVED NITROGEN SOURCE FOR ETHANOL FERMENTATION | July 2021 | July 2025 | Allow | 48 | 3 | 1 | No | No |
| 17370938 | METHODS AND COMPOSITIONS FOR ISOLATION AND RAPID DETECTION OF MICRO-ORGANISMS FROM BLOOD AND BODILY FLUIDS | July 2021 | October 2023 | Abandon | 27 | 1 | 1 | No | No |
| 17364578 | METHODS FOR DETERMINING ANTIBIOTIC SENSITIVITY | June 2021 | June 2024 | Allow | 35 | 2 | 0 | No | No |
| 17358878 | IMMUNE PRIMING TO ACCELERATE/ENHANCE IMMUNE RESPONSE THROUGH ADMINISTRATION OF NATURAL IMMUNE MODULATOR | June 2021 | March 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17415976 | PHARMABIOTIC TREATMENTS FOR METABOLIC DISORDERS | June 2021 | November 2024 | Abandon | 41 | 2 | 1 | No | No |
| 17348994 | Designer Peptide Opsonins | June 2021 | April 2025 | Abandon | 46 | 3 | 1 | Yes | No |
| 17311783 | A PROCESS FOR PRODUCTION OF NIGERICIN FROM STREPTOMYCES SP. MCC-0151 | June 2021 | February 2024 | Allow | 32 | 1 | 0 | No | No |
| 17337052 | TREATING OR PREVENTING RESPIRATORY INFECTION | June 2021 | February 2024 | Allow | 33 | 1 | 1 | Yes | No |
| 17327081 | ACE2 fusion proteins and uses thereof | May 2021 | June 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17245060 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | April 2021 | October 2023 | Abandon | 29 | 1 | 1 | No | No |
| 17239866 | NOVEL ANTI-PD-1 ANTIBODIES | April 2021 | December 2022 | Allow | 20 | 0 | 0 | Yes | No |
| 17232301 | Treatment Methodology for the Prevention and Control of Viral Infections | April 2021 | April 2023 | Abandon | 24 | 1 | 0 | No | No |
| 17187976 | INTRACELLULAR NON-GENETIC MODIFICATION OF MICROORGANISMS USING PROTEIN IONIC LIQUIDS | March 2021 | May 2023 | Allow | 27 | 2 | 1 | No | No |
| 17187771 | METHODS OF REDUCING POLYSORBATE DEGRADATION IN DRUG FORMULATIONS | February 2021 | April 2025 | Abandon | 49 | 4 | 1 | No | No |
| 17187697 | GENETICALLY MODIFIED FUNGAL CELLS AND METHODS USEFUL FOR PRODUCING PRESPATANE | February 2021 | August 2023 | Allow | 29 | 1 | 1 | No | No |
| 17184177 | TREATEMENT OF PATHOGEN INFECTIONS FORMULATIONS AND METHODS FOR USE | February 2021 | December 2022 | Allow | 22 | 1 | 1 | Yes | No |
| 17266952 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INFLAMMATORY DISEASES | February 2021 | May 2024 | Abandon | 39 | 1 | 1 | No | No |
| 17168983 | PANICUM VIRGATUM SOSEKI PROTEIN SOK2, CODING GENE AND APPLICATION THEREOF | February 2021 | October 2023 | Allow | 33 | 2 | 1 | No | No |
| 17160132 | COMPOSITIONS INCLUDING PROBIOTIC BACTERIA FOR THE EXPRESSION AND SECRETION OF ENTEROCINS TO CONTROL CLOSTRIDIA PERFRINGENS-INDUCED NECROTIC ENTERITIS IN LIVESTOCK AND RELATED METHODS | January 2021 | June 2024 | Allow | 40 | 2 | 1 | No | No |
| 17260693 | THERMOSTABLE PHYCOBILIPROTEINS PRODUCED FROM RECOMBINANT ARTHROSPIRA | January 2021 | January 2025 | Allow | 48 | 3 | 1 | Yes | No |
| 17257422 | AQUEOUS TOPICAL COMPOSITIONS COMPRISING VIABLE PROBIOTIC BACTERIA | December 2020 | May 2025 | Abandon | 52 | 2 | 1 | No | Yes |
| 17255557 | DIABETES-ALLEVIATING OR ANTIOXIDANT COMPOSITION COMPRISING YEAST EXTRACT AND METHOD FOR PREPARING YEAST EXTRACT | December 2020 | March 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17247532 | HIGH-AFFINITY MYCOBACTERIUM TUBERCULOSIS CAPSULE-SPECIFIC HUMAN MONOCLONAL ANTIBODY | December 2020 | December 2022 | Allow | 24 | 1 | 1 | Yes | No |
| 17251410 | Therapeutic Methods Using Bacterial Strains Which are Capable of Increasing Adenosine Levels | December 2020 | December 2024 | Abandon | 48 | 3 | 1 | No | No |
| 17247294 | STAPHYLOCOCCAL COAGULASE ANTIGENS AND METHODS OF THEIR USE | December 2020 | April 2023 | Abandon | 28 | 0 | 1 | No | No |
| 15734107 | COMPOSITION FOR TREATING OR PREVENTING COLORECTAL DISEASE CONTAINING CONSTRUCT FOR EXPRESSION OF P8 PROTEIN DERIVED FROM LACTIC ACID BACTERIA | December 2020 | December 2024 | Allow | 48 | 2 | 0 | Yes | No |
| 17095178 | METHOD OF DIAGNOSING PERIODONTAL CONDITIONS USING SALIVARY PROTEIN MARKERS | November 2020 | December 2023 | Abandon | 37 | 2 | 0 | No | No |
| 17089370 | COMPOSITION | November 2020 | October 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17082035 | COMPOSITION FOR DELIVERY OF PROTEIN THERAPEUTICS THROUGH ORAL, SUBLINGUAL AND BUCCAL ROUTE | October 2020 | November 2023 | Abandon | 37 | 2 | 0 | No | No |
| 17048155 | TICK VACCINE | October 2020 | June 2025 | Abandon | 56 | 4 | 0 | No | No |
| 17073075 | COMPOSITIONS AND METHODS FOR INTRODUCTION OF ODD-CHAIN FATTY ACIDS INTO POULTRY EGGS | October 2020 | May 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17070747 | Treatment of Uterine Fibroids using Purified Collagenase | October 2020 | September 2023 | Allow | 35 | 3 | 0 | No | No |
| 17046761 | OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE | October 2020 | June 2023 | Allow | 32 | 0 | 0 | No | No |
| 16981200 | METHODS OF CULTIVATING BORDETELLA SPECIES | September 2020 | January 2024 | Allow | 40 | 1 | 1 | No | No |
| 17020803 | METHODS FOR SIMULTANEOUS MEASUREMENT OF MULTIPLE BIOLOGICAL SIGNALS FROM SPECTRALLY IDENTICAL FLUORESCENT REPORTERS | September 2020 | May 2023 | Allow | 32 | 1 | 1 | No | No |
| 17016849 | Method for Assessing the Effects of Hypoxia on Tissues | September 2020 | January 2023 | Allow | 28 | 2 | 0 | No | No |
| 16979117 | RECOMBINANT ALKALINE PHOSPHATASE FOR USE IN TREATING SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY | September 2020 | August 2024 | Allow | 47 | 2 | 0 | No | No |
| 16976485 | ANTI-PLA2-GIB ANTIBODIES AND THE USES THEREOF | August 2020 | March 2024 | Abandon | 42 | 0 | 1 | No | No |
| 16985979 | IMMUNOGENIC COMPOSITIONS | August 2020 | June 2023 | Allow | 34 | 3 | 1 | No | No |
| 16932319 | COMPOSITIONS AND METHODS FOR THE DEPLETION OF CD134+ CELLS | July 2020 | April 2024 | Abandon | 45 | 0 | 1 | No | No |
| 16946861 | MALARIAL VACCINATION METHODS AND REGIMENS | July 2020 | April 2024 | Abandon | 45 | 3 | 1 | No | No |
| 16959016 | COMPOSITION COMPRISING PROBIOTICS AND POLYPEPTIDE HAVING BINDING AFFINITY FOR IGE AND USE THEREOF | June 2020 | June 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16888576 | IMMUNOTHERAPY OF SOLID TUMORS BY VACCINATION WITH TRANSGENIC LEISHMANIA EXPRESSING CANCER VACCINES AND WITH RECOMBINANT VACCINES WITH LEISHMANIA AS ADJUVANTS | May 2020 | December 2023 | Abandon | 43 | 2 | 0 | No | No |
| 16761004 | COMPOSITITION AND USES OF TELEOST INVARIANT CHAIN TO ENHANCE T CELL RESPONSE TO A VACCINE | May 2020 | October 2023 | Allow | 42 | 4 | 1 | No | No |
| 16847994 | METHOD FOR MEASURING A BIOMARKER IN A BIOLOGICAL SAMPLE OF AN IPAF PATIENT | April 2020 | April 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 16641630 | EVOLUTION OF BONT PEPTIDASES | February 2020 | March 2024 | Allow | 49 | 3 | 1 | No | No |
| 16639300 | Vaccines Against Leishmania Infection | February 2020 | December 2023 | Abandon | 46 | 3 | 1 | Yes | No |
| 16619503 | MICROBIAL COMPOSITIONS | December 2019 | August 2022 | Allow | 33 | 2 | 1 | Yes | No |
| 16493975 | Methods and Compositions for Treating Obesity, Inflammation, or Metabolic Disorders with Bacteriophages | September 2019 | November 2023 | Abandon | 50 | 2 | 1 | No | No |
| 16484080 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING PANCREATIC CANCERS | August 2019 | March 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16475654 | ANTIBODY FRAGMENTS FOR THE TREATMENT OF BIOFILM-RELATED DISORDERS | July 2019 | June 2024 | Allow | 60 | 4 | 2 | Yes | No |
| 16474940 | MICROPARTICLES FROM STREPTOCOCCUS PNEUMONIAE AS VACCINE ANTIGENS | June 2019 | February 2023 | Allow | 44 | 5 | 0 | Yes | No |
| 16429474 | Compositions for in vivo Expression of Therapeutic Sequences in the Microbiome | June 2019 | October 2023 | Abandon | 52 | 4 | 2 | Yes | No |
| 16462941 | Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof | May 2019 | May 2024 | Allow | 59 | 3 | 0 | Yes | No |
| 16328175 | USE OF MALTODEXTRIN AS AN EXCIPIENT | February 2019 | August 2023 | Abandon | 54 | 1 | 0 | No | No |
| 16253392 | SYSTEMS AND METHODS FOR ALTERING MICROBIOME TO REDUCE DISEASE RISK AND MANIFESTATIONS OF DISEASE | January 2019 | June 2024 | Abandon | 60 | 8 | 2 | Yes | No |
| 16204674 | MATERIALS AND METHODS RELATING TO ANTIBODY TARGETS FOR TUBERCULOSIS SEROLOGY | November 2018 | May 2023 | Abandon | 54 | 5 | 1 | Yes | No |
| 16302938 | COMPOSITIONS AND METHODS FOR THE EXPRESSION OF EUKARYOTIC OLIGOSACCHARIDES ON BACTERIAL OUTER MEMBRANE VESICLES | November 2018 | May 2025 | Abandon | 60 | 3 | 1 | No | Yes |
| 16158506 | PROTEIN FOR RAPID, EFFICIENT CAPTURE OF ANTIGENS | October 2018 | March 2023 | Allow | 53 | 3 | 1 | Yes | No |
| 16092096 | ANTI-BACTERIAL COMPOSITIONS COMPARING LYTIC MODIFIED BACTERIOPHAGE ENGINEERED TO INFECT AND KILL DIFFERENT TARGET BACTERIA | October 2018 | March 2023 | Allow | 53 | 1 | 1 | No | No |
| 16050312 | Method for Precise Identification, Targeting and Delivery of Directed Therapies with the Use of Bacteria for the Destruction of Cancerous Cells | July 2018 | October 2020 | Abandon | 26 | 8 | 0 | Yes | Yes |
| 14777985 | METHOD OF TREATMENT | September 2015 | August 2023 | Allow | 60 | 14 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DICKENS, AMELIA NICOLE.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DICKENS, AMELIA NICOLE works in Art Unit 1645 and has examined 93 patent applications in our dataset. With an allowance rate of 43.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.
Examiner DICKENS, AMELIA NICOLE's allowance rate of 43.0% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by DICKENS, AMELIA NICOLE receive 2.13 office actions before reaching final disposition. This places the examiner in the 72% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by DICKENS, AMELIA NICOLE is 37 months. This places the examiner in the 13% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +28.1% benefit to allowance rate for applications examined by DICKENS, AMELIA NICOLE. This interview benefit is in the 79% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 22.4% of applications are subsequently allowed. This success rate is in the 19% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 12.5% of cases where such amendments are filed. This entry rate is in the 7% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants file petitions regarding this examiner's actions, 72.0% are granted (fully or in part). This grant rate is in the 88% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.0% of allowed cases (in the 79% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.